ライフサイエンスコーパス: hemorrhagic stroke

1 n of ischemic injury, and presumed perinatal hemorrhagic stroke.

2 ety and feasibility of early BP reduction in hemorrhagic stroke.

3 target molecule to limit brain damage during hemorrhagic stroke.

4 disorders, including myopathy, glaucoma and hemorrhagic stroke.

5 formations (bAVMs) are an important cause of hemorrhagic stroke.

6 ation in the brain that are a major cause of hemorrhagic stroke.

7 apillaries, leading to headache, seizure and hemorrhagic stroke.

8 , 1.18 (1.06-1.31), and 1.54 (1.27-1.87) for hemorrhagic stroke.

9 ents a promising neuroprotective strategy in hemorrhagic stroke.

10 scular abnormalities that cause seizures and hemorrhagic stroke.

11 f future therapeutic interventions following hemorrhagic stroke.

12 participants with incident strokes; 14% had hemorrhagic stroke.

13 ight striatum to mimic the natural events of hemorrhagic stroke.

14 tudy of the pathophysiology and treatment of hemorrhagic stroke.

15 positive for ischemic stroke and inverse for hemorrhagic stroke.

16 investigating the complex pathophysiology of hemorrhagic stroke.

17 e prone to rupture, resulting in seizures or hemorrhagic stroke.

18 hemic stroke), and 5 were presumed perinatal hemorrhagic stroke.

19 ary GL was associated with a greater risk of hemorrhagic stroke.

20 ed number of patients with liver disease and hemorrhagic stroke.

21 uggest that CEE had an effect on the risk of hemorrhagic stroke.

22 , seizures, focal neurological deficits, and hemorrhagic stroke.

23 or ischemic stroke and 0.64 (0.35, 1.18) for hemorrhagic stroke.

24 ve been associated with an increased risk of hemorrhagic stroke.

25 was associated with lower risk of total and hemorrhagic stroke.

26 or for total and ischemic stroke but not for hemorrhagic stroke.

27 ed to the end of 1998 for thromboembolic and hemorrhagic stroke.

28 n shown to play a role in the progression of hemorrhagic stroke.

29 relationship between alcohol consumption and hemorrhagic stroke.

30 verall stroke rate by half and did not cause hemorrhagic stroke.

31 emic stroke and 1.36 (95% CI, 0.48-3.82) for hemorrhagic stroke.

32 r long-chain omega-3 PUFA intake and risk of hemorrhagic stroke.

33 th an increased risk of stroke, particularly hemorrhagic stroke.

34 rin regularly, but is not related to risk of hemorrhagic stroke.

35 olyunsaturated fatty acid intake and risk of hemorrhagic stroke.

36 and rupture of the vessel wall, resulting in hemorrhagic stroke.

37 e cerebral vessel wall and, in severe cases, hemorrhagic stroke.

38 t was found for ischemic stroke, but not for hemorrhagic stroke.

39 ith separate analyses of ischemic stroke and hemorrhagic stroke.

40 bilities, including intractable seizures and hemorrhagic stroke.

41 association between alcohol consumption and hemorrhagic stroke.

42 mortality rate was 26% in the 2 weeks after hemorrhagic stroke.

43 e that aspirin therapy increases the risk of hemorrhagic stroke.

44 studies have suggested it increases risk of hemorrhagic stroke.

45 actors for ischemic and total stroke but not hemorrhagic stroke.

46 ischemic stroke; and HR 1.53 (0.91-2.59) for hemorrhagic stroke.

47 increased fatal and nonfatal GI bleeding and hemorrhagic stroke.

48 ted with increased risk of stroke overall or hemorrhagic stroke.

49 readmission, cardiovascular readmission, and hemorrhagic stroke.

50 ic stroke, and 0.80 (95% CI: 0.61, 1.04) for hemorrhagic stroke.

51 hould not aggravate outcomes associated with hemorrhagic stroke.

52 e debilitating ischemia and life-threatening hemorrhagic stroke.

53 95% CI, 0.41-0.57) per 1000 person-years for hemorrhagic stroke.

54 associated factors, and outcomes of neonatal hemorrhagic stroke.

55 impact of TSC in rat models of ischemic and hemorrhagic stroke.

56 in experimental models of both ischemic and hemorrhagic stroke.

57 centrations were not associated with risk of hemorrhagic stroke.

58 ersons and can be complicated by ischemic or hemorrhagic strokes.

59 n HCHWA-D, lead to recurrent and often fatal hemorrhagic strokes.

60 (IS), 15% transient ischemic attacks, and 9% hemorrhagic strokes.

61 e vascular inflammation leading to recurrent hemorrhagic strokes.

62 spirin increase gastrointestinal bleeding or hemorrhagic strokes?

63 nts/patient-year) were higher than those for hemorrhagic stroke (0.05), ischemic stroke (0.04), and p

64 infections (0.47 versus 0.27, P<0.001), and hemorrhagic stroke (0.07 versus 0.03, P=0.01).

65 n in total stroke (0.7% vs 2.0%; P=.007) and hemorrhagic stroke (0.1% vs 1.1%; P<.001).

66 Among HRT users and non-users, the rates of hemorrhagic stroke (0.40% vs. 0.42%, p = 1.00) and ische

67 .00), ischemic stroke (0.67; 0.48-0.93), and hemorrhagic stroke (0.45; 0.45-0.99) versus rivaroxaban.

68 4; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI,

69 the Watchman device had significantly fewer hemorrhagic strokes (0.15 vs. 0.96 events/100 patient-ye

70 stroke was 1.44 (95% CI, 1.09-1.90) and for hemorrhagic stroke, 0.82 (95% CI, 0.43-1.56).

71 rson-years; p < 0.001) and the incidences of hemorrhagic stroke (1.21 vs. 4.19 events per 1000 person

72 aining phenylpropanolamine and the risk of a hemorrhagic stroke, 1.23 (95 percent confidence interval

73 vated protein C-treated patients (0.25%) had hemorrhagic stroke, 107 (6.8%) had gastrointestinal blee

74 cident ischemic stroke and 140 with incident hemorrhagic stroke (18 participants had both during the

75 chemic stroke, 1.69 (95% CI, 1.34-2.15); and hemorrhagic stroke, 2.18 (95% CI, 1.48-3.20), while cons

76 uses of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure

77 s; summary RR: 1.13; 95% CI: 0.99, 1.28), or hemorrhagic stroke (3 cohorts; summary RR: 1.09; 95% CI:

78 The mortality rate was higher for hemorrhagic stroke (68%) than for ischemic stroke (57%).

79 den death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2).

80 h retinal vein occlusion had higher risks of hemorrhagic stroke (adjusted HR, 2.54 [95% CI, 1.50-4.30

81 2003, amphetamine abuse was associated with hemorrhagic stroke (adjusted odds ratio [OR], 4.95; 95%

82 ence interval [CI], 0.48-0.82); 9 and 19 had hemorrhagic strokes (adjusted RR, 0.46; 95% CI, 0.21-1.0

83 data from 204 591 patients with ischemic and hemorrhagic stroke admitted to 1563 Get With the Guideli

84 In addition to its role in hemorrhagic stroke, advanced cerebral amyloid angiopathy

85 The delayed timing of major and hemorrhagic stroke after revascularization suggests that

86 of AMI, and women are at increased risk for hemorrhagic stroke after thrombolytic therapy.

87 hemic stroke (aHR = 2.03, P = .003), but not hemorrhagic stroke (aHR = 1.24, P = .696), than the cont

88 9; 95% confidence interval [CI], 1.40-1.80), hemorrhagic stroke (aHR, 2.37; 95% CI, 1.90-2.96), myoca

89 on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stro

90 aining phenylpropanolamine and the risk of a hemorrhagic stroke and 3.13 (95 percent confidence inter

91 myloid angiopathy [CAA]) is a major cause of hemorrhagic stroke and a likely contributor to vascular

92 are most sensitive to the relative risk for hemorrhagic stroke and CVD mortality but are affected by

93 Excess risk for hemorrhagic stroke and gastrointestinal bleeding with as

94 of arterial vessels, has been implicated in hemorrhagic stroke and is present in most cases of Alzhe

95 The 2 fundamental subtypes of stroke are hemorrhagic stroke and ischemic stroke.

96 Using a rodent model of hemorrhagic stroke and next-generation proteomic and met

97 g BID) compared with rivaroxaban, as well as hemorrhagic stroke and nondisabling stroke.

98 otentially useful treatment in patients with hemorrhagic stroke and perhaps other acute brain injurie

99 ars of age, it may increase the incidence of hemorrhagic stroke and result in a similar rate of disab

100 iety of neurological disabilities, including hemorrhagic stroke and seizures.

101 d conditions such as traumatic brain injury, hemorrhagic stroke and uncontrolled surgical bleeding.

102 Intracerebral hemorrhagic stroke and vascular dementia are age- and hy

103 yocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bl

104 yocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bl

105 vascular malformations, which may result in hemorrhagic strokes and neurological deficits.

106 Incident strokes, excluding hemorrhagic strokes and strokes of cardiac origin, were

107 for myocardial infarction, ischemic stroke, hemorrhagic stroke, and cardiovascular mortality and unt

108 s of being transferred included younger age, hemorrhagic stroke, and higher stroke severity, but havi

109 l reductions in major bleeding, particularly hemorrhagic stroke, and mortality.

110 protective benefits on all-cause mortality, hemorrhagic stroke, and new-onset dialysis in HCV-infect

111 dial infarction (AMI), ischemic stroke (IS), hemorrhagic stroke, and new-onset dialysis were evaluate

112 e menopause and gestational hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm deliv

113 rdial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other cardiovascular [CV] d

114 ich triggers small-vessel disease, recurrent hemorrhagic strokes, and age-related macroangiopathy.

115 % of the population and accounts for 500,000 hemorrhagic strokes annually in mid-life (median age 50)

116 Ischemic stroke, hemorrhagic stroke, any stroke, and stroke mortality.

117 Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year aft

118 ven protective for myocardial infarction and hemorrhagic stroke ( approximately 2-4 drinks: relative

119 High rates of head CT use for patients with hemorrhagic stroke are frequently observed, without an a

120 ther pursued as targets for the treatment of hemorrhagic stroke as adjuvant treatment for stroke pati

121 , the risks of gastrointestinal bleeding and hemorrhagic strokes associated with aspirin use outweigh

122 r recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year

123 P=0.004), with no difference in the rates of hemorrhagic stroke between the active and placebo arms (

124 atment effect was observed within 1 year for hemorrhagic strokes but was not seen until the second ye

125 The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals

126 gulation, LAAC resulted in improved rates of hemorrhagic stroke, cardiovascular/unexplained death, an

127 om 16 trials with 55462 participants and 108 hemorrhagic stroke cases were analyzed.

128 ding transient ischemic attack, ischemic and hemorrhagic stroke, cerebral venous thrombosis, and nons

129 gs significantly increase the probability of hemorrhagic stroke: coma (likelihood ratio [LR], 6.2; 95

130 c stroke, and 0.82 (95% CI 0.43 to 1.58) for hemorrhagic stroke compared with women with BMI <25 kg/m

131 Aside from hemorrhagic stroke, corresponding associations of cardio

132 However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascul

133 or nonmajor clinically relevant bleeding and hemorrhagic stroke during treatment.

134 d hemorrhagic (gastrointestinal bleeding and hemorrhagic stroke) events occurring outside of the hosp

135 2) bleeding (composite of readmission due to hemorrhagic stroke, gastrointestinal bleeding, bleeding

136 ial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of

137 d Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) study.

138 and no controlled trials of hypothermia for hemorrhagic stroke have been performed.

139 ge was not associated with increased risk of hemorrhagic stroke (hazard ratio, 0.94; 95% confidence i

140 receiving the device had significantly fewer hemorrhagic strokes (hazard ratio 0.22, P=0.004); (2) a

141 epatobiliary, and neurocognitive events; and hemorrhagic stroke, heart failure, cancer, and noncardio

142 chemic stroke (HR, 1.27; 95% CI, 1.23-1.32), hemorrhagic stroke (HR, 1.36; 95% CI, 1.26-1.46), myocar

143 , ischemic stroke (HR, 1.27; 1.02-1.59), and hemorrhagic stroke (HR, 1.70; 1.01-2.84).

144 n E was associated with an increased risk of hemorrhagic stroke (HR, 1.74 [95% CI, 1.04-2.91]; P = .0

145 Hemorrhagic stroke (HS), ie, subarachnoid hemorrhage and

146 e, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomy

147 kely to be older, smokers, have a history of hemorrhagic stroke, hypothyroidism, and dementia, and le

148 mic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year).

149 performed for elderly patients admitted for hemorrhagic stroke in 2008-2009, with 1-year follow-up t

150 t ischemic attack (TIA), ischemic stroke, or hemorrhagic stroke in adults aged 18 through 50 years ad

151 nalysis in men showed no increased risk of a hemorrhagic stroke in association with the use of cough

152 in children with SCA without screening), and hemorrhagic stroke in children and adults with SCA (3% a

153 The mortality of hemorrhagic stroke in children is lower than that in adu

154 n young people and contribute to half of all hemorrhagic stroke in children.

155 Ischemic or hemorrhagic stroke in hospitalized and nonhospitalized p

156 coronary heart disease, ischemic stroke, and hemorrhagic stroke in husbands were 1.13 (95% confidence

157 may outweigh its adverse effects on risk of hemorrhagic stroke in most populations.

158 There was no increase in hemorrhagic stroke in patients on pravastatin compared w

159 diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-li

160 ivating blood vessels, prevents ischemic and hemorrhagic stroke in spontaneously hypertensive, geneti

161 Conversely, the incidence of hemorrhagic stroke in SS patients was highest among pati

162 onstrated a higher risk of both ischemic and hemorrhagic stroke in subjects with COPD and revealed th

163 nited States because of an increased risk of hemorrhagic stroke in women.

164 remedies, is an independent risk factor for hemorrhagic stroke in women.

165 Fs, 3262 MIs, 2039 ischemic strokes, and 405 hemorrhagic strokes in men and 1207 HFs, 1504 MIs, 1561

166 There was a tendency toward more major hemorrhagic strokes in symptomatic than in asymptomatic

167 d, beyond 30 days, to the occurrence of more hemorrhagic strokes in the TAVR group (2.2% vs. 0.6%, P=

168 and meta-analysis suggest that the risk for hemorrhagic strokes in women is not statistically signif

169 Fs, 1504 MIs, 1561 ischemic strokes, and 294 hemorrhagic strokes in women.

170 excess risk of death from ischemic, but not hemorrhagic, stroke in US black children has decreased o

171 BMI increases the risk of both ischemic and hemorrhagic stroke incidence, and stroke mortality in Ch

172 charge diagnosis codes for acute ischemic or hemorrhagic stroke (International Classification of Dise

173 Hemorrhagic stroke is a significant cause of morbidity a

174 Neonatal hemorrhagic stroke is more common than previously report

175 This excess risk of hemorrhagic stroke is particularly high in patients rece

176 treatment of ischemic strokes, treatment of hemorrhagic stroke is progressing more slowly.

177 mes were arrhythmia, cerebrovascular events, hemorrhagic stroke, ischemic stroke, coronary revascular

178 Italian kindred who presented with recurrent hemorrhagic strokes late in life, between 60 and 70 year

179 articipants; and occurrences of ischemic and hemorrhagic stroke, major extracranial bleeding, and dea

180 reports have suggested that the incidence of hemorrhagic stroke may be greater on hemodialysis as com

181 inant ADAMTS13 did not enhance bleeding in a hemorrhagic stroke model.

182 The ethnic disparity in hemorrhagic stroke mortality, however, remained relative

183 fluid (CSF) from patients with ischemic and hemorrhagic stroke (n=25) and in contemporary controls (

184 Dietary GL was associated with hemorrhagic stroke [n = 165; relative risk = 1.44 compar

185 The clinical epidemiology of neonatal hemorrhagic stroke (NHS) remains undefined, hindering th

186 All 3 hemorrhagic strokes occurred in the placebo group.

187 kes occurred within 48 hours of PCI, and all hemorrhagic strokes occurred within 48 hours.

188 associated with an absolute risk increase in hemorrhagic stroke of 12 events per 10000 persons (95% C

189 f products containing phenylpropanolamine to hemorrhagic stroke, often after the first use of these p

190 the risk of severe complications, including hemorrhagic stroke or death.

191 The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.

192 e examined for the occurrence of ischemic or hemorrhagic stroke or transient ischemic attack either b

193 associated with a higher risk of death after hemorrhagic stroke (OR, 2.63; 95% CI, 1.07-6.50).

194 is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts th

195 ugh weight change was not related to risk of hemorrhagic stroke (P for trend=.20), a direct relations

196 a significant reduction in deaths caused by hemorrhagic stroke (P=0.01).

197 much higher hospital mortality rate than non-hemorrhagic stroke patients (53% versus 15%, P<0.001), w

198 Hemorrhagic stroke patients had a much higher hospital m

199 Concentrations of CSF FFAs from ischemic and hemorrhagic stroke patients obtained within 48 h of the

200 At discharge, hemorrhagic stroke patients were more likely to be disab

201 endothelial cells of hemorrhagic lesions of hemorrhagic stroke patients.

202 itive impairment and antihypertensives among hemorrhagic stroke patients.

203 Compared with hemorrhagic stroke, patients with ischemic stroke had hi

204 GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 1000 person-years of aspirin expo

205 Because of its potential association with hemorrhagic strokes, phenylpropanolamine has been largel

206 ore, astrocytes may be a possible target for hemorrhagic stroke prevention and therapy.

207 06; 95% CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95% CI, 1.0

208 imes higher in the age group 55 to 64 years; hemorrhagic stroke rates were 5 to 6 times (age <55 year

209 Hemorrhagic stroke rates were similar in both age groups

210 and a nonsignificant increase in the risk of hemorrhagic stroke (relative risk, 1.24; 95 percent conf

211 erval: 0.52, 0.83; p(trend) = 0.001) and for hemorrhagic stroke, relative risk = 0.51 (95% confidence

212 1,256 and 164 persons developed ischemic and hemorrhagic stroke, respectively.

213 e of refined carbohydrate is associated with hemorrhagic stroke risk, particularly among overweight o

214 take was inversely associated with total and hemorrhagic stroke risk; for total stroke, relative risk

215 hest case volume (more than 50 patients with hemorrhagic stroke), risk-adjusted rates ranged from 8.0

216 In acute hemorrhagic stroke, SBP greater than 140 has been correl

217 Hemorrhagic stroke seemed to be more prevalent in the st

218 ption activity is a key pathogenic factor in hemorrhagic stroke, seizure activity, and central nervou

219 n the brain and are strongly associated with hemorrhagic stroke, seizures, and other neurological dis

220 he central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and f

221 ult rats were subjected to ischemic strokes, hemorrhagic strokes, sham surgeries, kainate-induced sei

222 Incidence of ischemic stroke, hemorrhagic stroke (subarachnoid or intraparenchymal hem

223 The results were similar when ischemic and hemorrhagic stroke subtypes were considered separately.

224 Results were similar for ischemic and hemorrhagic stroke subtypes, for RBC fatty acids, and in

225 rove valuable for patients with ischemic and hemorrhagic stroke, such as earlier recognition, more ac

226 Aspirin increased the risk for hemorrhagic strokes (summary odds ratio, 1.4 [CI, 0.9 to

227 was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascula

228 tion, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute

229 ute cognitive decline or seizure rather than hemorrhagic stroke, the primary clinical presentation in

230 For combined ischemic and hemorrhagic strokes, the intention-to-treat hazard ratio

231 For hemorrhagic stroke there was a nonsignificant inverse re

232 With respect to the risk of hemorrhagic stroke, there was a positive interaction bet

233 myocardial infarction, ischemic stroke, and hemorrhagic stroke using DerSimonian and Laird random-ef

234 The rate of hemorrhagic stroke was 0.24% per year in the apixaban gr

235 7.7% (95% CI, 6.4-8.8%) in men; the risk of hemorrhagic stroke was 0.8% (95% CI, 0.4-1.2%) and 1.3%

236 The adjusted odds ratio for hemorrhagic stroke was 1.14 (95 percent confidence inter

237 Hemorrhagic stroke was associated with low steady-state

238 Power to detect effects on hemorrhagic stroke was limited.

239 An increase in hemorrhagic stroke was not seen at low LDL-C levels.

240 o received thrombolytic therapy, the rate of hemorrhagic stroke was not significantly different for u

241 A reduction in hemorrhagic stroke was observed with rivaroxaban in pati

242 The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg gr

243 ease and cerebrovascular disease, especially hemorrhagic stroke, was higher in every Asian-American s

244 Rates of hemorrhagic stroke were 0.13% and 0.14%/y.

245 The pooled relative risks of hemorrhagic stroke were 2.24 (95% CI, 1.19-4.21) in wome

246 Associations of vitamin intake with hemorrhagic stroke were also nonsignificant, but the CIs

247 09 without a previous history of ischemic or hemorrhagic stroke were identified from Taiwan's Nationa

248 age, 79.6 years; 31 377 women [58.9%]) with hemorrhagic stroke were identified in the study period.

249 0-mg groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across quint

250 Furthermore, 65% of hemorrhagic strokes were noted post-procedure and pre-di

251 okes (including 403 ischemic strokes and 269 hemorrhagic strokes) were documented.

252 intake was associated with elevated risk of hemorrhagic stroke when the extreme quintiles were compa

253 R: 1.94) were multivariable risk factors for hemorrhagic stroke, whereas female (HR: 1.84) and histor

254 odifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, a

255 disorders including ischemic infarction and hemorrhagic stroke who are heterozygous for factor V Lei

256 ected associations were an increased risk of hemorrhagic stroke with lower sodium-to-potassium ratio

257 Men have an increased risk for hemorrhagic strokes with aspirin use.

258 ificant inverse relation between obesity and hemorrhagic stroke, with the highest risk among women in

259 major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization.